Andrew F Russo

USPTO Granted Patents = 13 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 49(Granted Patents)

Company Filing History:

11 out of 902

University of Iowa Research Foundation

Alderbio Holdings LLC

patents

where one patent can have more than one assignee

Years Active: 1996-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11993648 - Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion (2024-05-28),

2. 11325967 - Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light a version in subjects in need thereof, especially migraine sufferers (2022-05-10),

3. 11027018 - Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels (2021-06-08),

4. 10981984 - Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion (2021-04-20),

5. 10844116 - Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia (2020-11-24),

6. 10765746 - Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels (2020-09-08),

7. 10266587 - Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers (2019-04-23),

8. 9855332 - Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels (2018-01-02),

9. 9708393 - Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers (2017-07-18),

10. 6159735 - Calcitonin/calcitonin gene related peptide enhancer element and (2000-12-11),

11. 615973 - Calcitonin/calcitonin gene related peptide enhancer element and (2000-12-12),

12. 5976788 - Calcitonin and calcitonin-gene related peptide enhancer element and (1999-11-02),

13. 5569604 - Calcitonin/calcitonin gene related peptide enhancer element and (1996-10-29),

Title: **Innovative Discoveries of Andrew F. Russo in the Field of Photophobia Treatment**

Introduction

Andrew F. Russo is a prominent inventor located in Iowa City, IA, whose work focuses on developing novel treatments for light sensitivity disorders. With a notable portfolio of 13 patents, Russo has contributed significantly to the understanding and management of conditions like PACAP-associated photophobia and migraines.

Latest Patents

Russo's latest patents explore groundbreaking methods for identifying and utilizing specific antibodies to treat photophobia. One of his key inventions involves a screening method for identifying anti-PACAP antibodies or antibody fragments that are potential therapeutic agents in managing PACAP-associated photophobia or light aversion. This innovation aims to create therapeutic compositions that can alleviate symptoms for individuals affected by these conditions.

Another significant patent details the use of anti-CGRP antibodies and their fragments to prevent photophobia in subjects, particularly migraine sufferers. This invention addresses the need for effective treatments for various disorders related to photophobia, such as migraines and cluster headaches. The patent outlines assays using transgenic Nestin/Ramp1 rodents which utilize a CGRP model to test the effectiveness of these antibodies and their ability to inhibit light sensitivity.

Career Highlights

Throughout his career, Andrew F. Russo has collaborated with esteemed institutions that have facilitated his research. Notably, he has worked with the University of Iowa Research Foundation, where he has been able to translate his innovative ideas into practical applications. Additionally, Russo has gained experience at H. Lundbeck A/S, where he furthered his expertise in pharmacological therapies.

Collaborations

Andrew F. Russo has worked alongside talented colleagues, including Adisa Kuburas and John A. Latham. Collaborating with other professionals allows him to enrich his research and contribute to the advancement of innovative treatments in his field.

Conclusion

Andrew F. Russo is a notable inventor whose contributions are paving the way for new therapies in the management of photophobia and associated disorders. His inventions reflect a dedication to improving the quality of life for those affected by light sensitivity. As he continues to innovate, the medical community eagerly anticipates the impact of his discoveries on treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.